▶주메뉴 바로가기
▶본문 바로가기
[ THE INVESTOR ] Robert Urban, head of Johnson & Johnson Innovation, is visiting Seoul this week to meet a few biotechnology companies in Korea where the company is seeking to create a partnering ...
[ THE INVESTOR ] Hanmi Pharmaceutical on April 10 unveiled nine new drug candidates in preclinical animal testing, including those for breast and lung cancer. They are among the 23 new drugs tha...
[THE INVESTOR] At age 4, an American toddler named Nicholas Volker was dying. Since he was born, the boy had suffered from an unknown disease that caused holes to continually form in his abdomen. ...
[ THE INVESTOR ] Celltrion has maintained the top position in the pharmaceutical and biotech industry in terms of operating profit for the sixth consecutive year since 2011, industry data showed ...
[ THE INVESTOR ] South Korea’s Genexine is attracting attention from global pharmaceutical companies as its long-acting human growth hormone treatment has shown positive interim data from phase ...
[ THE INVESTOR ] Samsung BioLogics on April 3 denied allegations that it used accounting fraud to boost its valuation ahead of its public listing last year, as South Korea’s finance regulator pre...
[ THE INVESTOR ] Celltrion Healthcare said on April 3 that it has launched a cheaper monitoring kit for its sister firm Celltrion 's biosimilar Remsima that calculates the correct does of the dr...
[ THE INVESTOR ] Celltrion Healthcare, the marketing affiliate of Celltrion , is expected to issue its initial public offering as early as September after its accounting woes pushed back the ori...
[ THE INVESTOR ] South Korea's biosimilar developer Celltrion on March 31 said it has filed two petitions to nullify Genentech’s patents for the breast cancer treatment Herceptin in the US before...
[ THE INVESTOR ] South Korea’s biopharmaceutical firm Alteogen said March 30 that it has signed a license deal with China’s Qilu Pharmaceutical to jointly develop and commercialize its biosimilar...
[ THE INVESTOR ] South Korea’s state financial watchdog on March 30 announced a special audit of Samsung BioLogics , following allegations of accounting fraud to show a surprise profit ahead of i...
[ THE INVESTOR ] South Korea’s Ministry of Food and Drug Safety on March 29 slapped 3M Korea and two local drugmakers with a temporary import, marketing and sales ban for breaching local pharmaceut...
[ THE INVESTOR ] South Korean drug makers are scurrying to launch a skin patch to treat patients with severe dementia as the country faces rapidly aging population. Boryung Pharmaceutical is dev...
[ THE INVESTOR ] South Korea’s Bukwang Pharmaceutical said on March 29 that it has racked up investment returns of over 400 percent by investing in CoLucid Pharmaceuticals which was recently acq...
[ THE INVESTOR ] Saving time and lowering costs are decisive factors for a contract manufacturing operator that produces biopharmaceutical products. And Samsung BioLogics is confident of achievin...
This week's DECODED X
Samsung's share in Chinese smartphone market falls to 3%
Celltrion’s earnings double on strong Remsima sales
SK hynix increases facility investment to W10tr
Hyundai Kona sales to exceed 10,000 units in July
Renault likely to produce Twizy in Korea
Samsung Bioepis heats up price war in Remicade biosimilar market
SK to invest W372b in Chinese logistics firm
